Liminatus Pharma and Iris Acquisition Corp Announce Completion of Business Combo

 Liminatus Pharma, LLC (“Liminatus” or the “Company”), a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, and Iris Acquisition Corp (“Iris”), a special purpose acquisition company backed by Arrow Capital, announced today the completion of their previously announced business combination (the “Business Combination”).

The combined company has been renamed Liminatus Pharma, Inc., and its common stock and warrants are expected to commence trading on The Nasdaq Stock Market LLC (“Nasdaq”) under the new ticker symbols “LIMN” and “LIMNW”, respectively, on May 1, 2025. The Business Combination was approved at a special meeting of Iris’s stockholders on March 4, 2025. Liminatus is developing novel cancer therapies that exploit the body’s immune system. The Company’s clinical candidate is a humanized anti CD47 monoclonal antibody. The next generation CD47 checkpoint inhibitor’s (code name: IBA101) initial indication is expected to be patients with advanced solid cancers including non-small cell lung cancer.

https://www.yourcentralvalley.com/business/press-releases/ein-presswire/808245465/liminatus-pharma-and-iris-acquisition-corp-announce-completion-of-business-combination/